Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq 21:00:00 19/04/2024 BST 5-day change 1st Jan Change
66.76 USD +0.91% Intraday chart for Gilead Sciences, Inc. -1.92% -17.59%

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fa3ed35a3b726ff856d88aec6e5f.W2tzWD9TXZrjXgBon35wCI_1fElV8hQ9w-cvyp3nl3o.FjFFDlYLabeLGGkKzBwVUry8DzEXiHxpl5JOheqK-ykXPTQRXjhk7tI3UQ~08c9243633df637b16bf82e1fcd68547
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89 MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79 MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91 MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29 MT
Oppenheimer Cuts Gilead Sciences Price Target to $105 From $115, Maintains Outperform Rating MT
UBS Adjusts Gilead Sciences Price Target to $81 From $80, Maintains Neutral Rating MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Wall St set for higher open as earnings, rate outlook in focus RE
Piper Sandler Adjusts Gilead Sciences Price Target to $95 From $100, Maintains Overweight Rating MT
TD Cowen Adjusts Gilead Sciences Price Target to $90 From $95, Maintains Outperform Rating MT
Cantor Fitzgerald Adjusts Gilead Sciences Price Target to $78 From $80, Maintains Neutral Rating MT
Leerink Partners Adjusts Gilead Sciences Price Target to $79 From $87, Maintains Market Perform Rating MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $84 From $90, Keeps Equalweight Rating MT
RBC Cuts Price Target on Gilead Sciences to $76 From $78, Notes Core Business Headwinds, Pipeline Setbacks; Keeps Sector Perform Rating MT
That's good enough for investors Our Logo
North American Morning Briefing : Rate Doubts Keep Pressure on Stocks; More Earnings in Focus DJ
MORNING BID AMERICAS-Rates rebound cools, China commands rally RE
Barclays Raises Gilead Sciences' Price Target to $85 From $82, Reiterates Equalweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
66.76 USD
Average target price
85.25 USD
Spread / Average Target
+27.69%
High Price Target
121 USD
Spread / Highest target
+81.25%
Low Price Target
69 USD
Spread / Lowest Target
+3.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

BMO Capital
Leerink Partners
UBS
Goldman Sachs
Morgan Stanley
Wells Fargo Securities
Mizuho Securities
Truist Securities
RBC Capital Markets
Oppenheimer
Piper Sandler
TD Cowen
Cantor Fitzgerald
Barclays
Deutsche Bank Securities
BofA Securities
HSBC
SVB Securities LLC
Cowen
Maxim
JPMorgan Chase
Argus
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK Elmar Kraus
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Consensus Gilead Sciences, Inc.